Business
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
Poster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":"\n\nPoster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer clinical trial.\n\n\nFinal safety conclusions are that GP2 immunotherapy is well tolerated and that no serious adverse events related to GP2 immunotherapy were reported over the full 5 year follow-up period.\n\n\nFinal 5 Year Data Set of GP2 Phase IIb Trial is Now Complete: Figure 1 of the poster shows a time series of the GP2 immunotherapy injections, adverse events (AE), immune response, and 100% disease-free survival (0% recurrence rate) in HER2 positive breast cancer patients over median 5 years. This time series highlights that the 10 GP2 immunotherapy injections over the first 2.5 years (as depicted by the 10 arrows) created a potent immune response that peaked at 6 months. The immune response includes injection site and systemic reactions (types of adverse events) that also peaked at 6 months. These adverse events are a positive sign that the immune system responded to GP2 immunotherapy and prevented metastatic breast cancer recurrence. Adverse events were temporally associated with GP2 injections and declined after GP2 injections ended.\n\n\n STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, presented an abstract and poster of the final 5 year GP2 Phase IIb clinical trial safety data at the 2021 ASCO Annual Meeting.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005374/en/Figure 1 of Poster Presentation 542 from 2021 ASCO Annual Meeting Showing GP2 Immunotherapy 5 Year Time Series of Dosing, Safety, Immune Response, and Disease Free Survival from Phase IIb Clinical Trial (Graphic: Business Wire)\nThe abstract can be viewed at the bottom of this press release, and the full poster, Figures 1-2, Tables 1-2, and an audio track of the poster by VP of Clinical & Regulatory Affairs Jaye Thompson can be accessed and downloaded at: https://greenwichlifesciences.com/clinical-trials/.\n\nIt has been previously reported that the completion of the GP2 immunotherapy (GP2+GM-CSF) Prim...